Keith Mayl, MD, PhD

Keith Mayl is a physician-scientist and the Associate Vice President of Neurodegenerative Disease Early Phase Clinical Development at Eli Lilly and Company. He is a recognized expert in neurodegeneration, specializing in ALS-FTD. He notably led first-in-human clinical trials for Qalsody (Tofersen), resulting in its approval, and holds a PhD from Kings College London.

Driven by a passion for patient advocacy, Keith focuses on accelerating the development of novel therapeutics for neurological diseases with high unmet needs. He actively engages with the global research community by participating in and chairing international symposiums and roundtables focused on advancing ALS research and challenging the status quo in clinical trials.

Unique fact: He played a pivotal leadership role in the clinical trials for the antisense oligonucleotide drug Qalsody, leading to its landmark approval for treating ALS.